Market Intel: Minimally Invasive Procedures Gaining Traction In BPH Treatment Market

Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Landmark studies of newer techniques have led the American Urological Association to update its guidelines.

BPH

Treatment of symptomatic benign prostate hyperplasia (BPH) has changed in recent years, with companies introducing innovative, minimally invasive device options that are increasingly seen as viable alternatives to risky surgical interventions.

BPH is a common urological condition that is characterized by the non-cancerous proliferation of prostate gland cells. It affects about 40% of men in their 50s and 90% of men...

More from Oncology

More from Device Area